Class Action Lawsuit Filed Against Gossamer Bio, Key Dates for Investors to Note

Investor Alert: Class Action Lawsuit Filed Against Gossamer Bio, Inc.

Pomerantz LLP recently announced a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS), focusing on potential instances of securities fraud involving the company's operations and disclosures. This lawsuit offers a critical opportunity for investors who suffered losses during the class period to seek justice and recovery.

Background of the Lawsuit

For investors in Gossamer, this lawsuit stems from the company's announcement on February 23, 2026, regarding the results of its Phase 3 PROSERA study, which evaluated the efficacy of seralutinib in treating pulmonary arterial hypertension. The study failed to achieve its primary endpoint, revealing that participants experienced only a modest improvement in their six-minute walk distance. Specifically, the study registered a +13.3 meter placebo-adjusted gain with a p-value of 0.0320, which did not meet the necessary alpha threshold of 0.025, leading to significant concerns about the reliability of Gossamer’s clinical data and communications.

Impact on Investors

Following the release of this disappointing news, Gossamer's stock price plunged by $1.71, marking an astonishing 80.13% decline and reducing the share price to approximately $0.42 on the same day. This dramatic drop highlights the potential losses incurred by shareholders, thus sparking the interest of legal experts who are now advocating for the rights of investors harmed by the company’s alleged misconduct.

Important Deadlines

For those affected, it is crucial to act promptly. Investors who bought or acquired Gossamer securities during the specified class period have until June 1, 2026, to request the court designate them as lead plaintiff in this class action. Interested investors are urged to contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by phone at 646-581-9980, and are advised to provide their mailing address, phone number, and the number of shares they purchased.

About Pomerantz LLP

Pomerantz LLP has established itself as a leader in the realm of corporate, securities, and antitrust class litigation, having been in operation for over 85 years. Founded by Abraham L. Pomerantz, recognized as a pioneer in securities class actions, the firm has successfully represented numerous clients seeking damages for securities fraud and corporate misconduct. Its commitment to fighting for investor rights is unwavering, and it has recovered significant damages for class members in a variety of cases.

Further Actions and Advice

Investors are encouraged to keep abreast of ongoing developments and deadlines related to the lawsuit against Gossamer Bio. As this lawsuit unfolds, staying informed could be pivotal for recovery efforts for shareholders affected by the company's actions. A comprehensive copy of the complaint can be accessed through the firm’s official website at www.pomerantzlaw.com.

In conclusion, this class action lawsuit presents a collective opportunity for investors to seek justice for their losses. Prompt action is advisable, and those wishing to participate should ensure they meet all necessary deadlines and provide the requisite information to their legal counsel.